Literature DB >> 1382915

Effects of lysine infusion on the renal metabolism of aprotinin (Trasylol) in man.

R Rustom1, P Maltby, J S Grime, H R Stockdale, M Critchley, J M Bone.   

Abstract

1. Aprotinin (Trasylol) is a cationic 6500 Da polypeptide that inhibits proteolytic enzymes, and when labelled with 99mTc it is a reproducible marker for the renal tubular turnover of small filtered proteins in man. Lysine potently inhibits tubular peptide uptake, and may thus depress the uptake and metabolism of aprotinin. This was investigated in 14 glomerulonephritic patients with normal renal function and variable proteinuria and in one healthy subject. 2. 99mTc-labelled aprotinin was given intravenously alone, and again 3 days later, immediately after the intravenous administration of 3-6 g of lysine, followed by an infusion over 1 h of 0.3-1.9 g of lysine/kg in individual patients. Activity over kidneys and in urine was measured over 24 h and chromatography was used to separate the undegraded peptide from free isotope. 3. At the low dosage of lysine (< 0.8 g/kg) given to six patients, kidney activity (representing tubular uptake) was unchanged, but early urine samples contained some undegraded aprotinin. Urinary excretion of free isotope, representing tubular metabolism, fell from 1.6 +/- 0.2% of dose/h with no lysine to 0.9 +/- 0.1% of dose/h in the 24 h after lysine, suggesting suppression of tubular aprotinin degradation. Corrected fractional degradation was calculated from the mean urinary excretion of free isotope over a given interval, determined by chromatography, divided by the mean cumulative kidney counts over this same interval, and this also fell after lysine from 0.06 +/- 0.006 to 0.03 +/- 0.006 h-1 (P < 0.005) between 3.75 and 24 h.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1382915     DOI: 10.1042/cs0830295

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  2 in total

Review 1.  Impact of physiochemical properties on pharmacokinetics of protein therapeutics.

Authors:  Rajan Swami; Aliasgar Shahiwala
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-04-14       Impact factor: 2.441

2.  Pretargeting in tumored mice with radiolabeled morpholino oligomer showing low kidney uptake.

Authors:  Guozheng Liu; Jiang He; Shuping Dou; Suresh Gupta; Jean-Luc Vanderheyden; Mary Rusckowski; Donald J Hnatowich
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-12-23       Impact factor: 9.236

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.